(Bloomberg) -- As Novo Nordisk A/S shares head for their worst month in more than two decades, the days when the Danish drugmaker was valued at more than $600 billion are becoming a distant memory.

There is a long-running health crisis impacting the modern world. According to the World Health Organization, one in eight people worldwide were living with obesity as of 2022. Obesity causes ...

LONDON, March 27 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab shares have fallen 25% so far in March and are on track for their biggest monthly drop since July 2002, as investor worries ...

Novo Nordisk (NYSE:NVO) today announced that the U.S. Food and Drug Administration (FDA) has approved an additional indication for ...

Europe’s largest pharmaceutical firm, Novo Nordisk, saw its stocks tumble 27% in March, marking their worst monthly performance since July 2002. As of market close on 31 March, the Danish firm ...

Claim your 7-day free trial now. Novo Nordisk A/S NVO on Saturday presented the full results from the Phase 3b STRIDE peripheral artery disease (PAD) outcomes trial. The study evaluated the once ...

This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order ...

Novo Nordisk to Pay $2 Billion for New Weight Loss Drug TUESDAY, March 25, 2025 (HealthDay News) -- Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up to $2 billion ...

Novo Nordisk already has broad FDA approvals in hand for its injected semaglutide products Ozempic and Wegovy to reduce the risk of cardiovascular events. Now the Danish company is hoping to score ...

The popularity of Novo Nordisk's Ozempic and Wegovy has attracted competitors and created supply constraints. Novo Nordisk's next-generation weight loss drug disappointed investors in Phase III ...